Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 14;8(3):171.
doi: 10.3390/tropicalmed8030171.

Zika, Flavivirus and Malaria Antibody Cocirculation in Nigeria

Peter Asaga Mac  1 , Axel Kroeger  2 , Theo Daehne  1 , Chukwuma Anyaike  3 , Raman Velayudhan  4 , Marcus Panning  1
Affiliations

Zika, Flavivirus and Malaria Antibody Cocirculation in Nigeria

Peter Asaga Mac et al. Trop Med Infect Dis. .

Abstract

Introduction. Arboviruses and malaria pose a growing threat to public health, affecting not only the general population but also immunocompromised individuals and pregnant women. Individuals in vulnerable groups are at a higher risk of severe complications from the co-circulation and transmission of ZIKV, malaria, and FLAVI fever. In sub-Saharan countries, such as Nigeria, these mosquito-borne infections have clinical presentations that overlap with other diseases (dengue, West Nile virus, and Japanese encephalitis, chikungunya, and O'nyong o'nyong virus), making them a diagnostic challenge for clinicians in regions where they co-circulate. Vertical transmission can have a devastating impact on maternal health and fetal outcomes, including an increased risk of fetal loss and premature birth. Despite the global recognition of the burden of malaria and arboviruses, particularly ZIKV and other flaviviruses, there is limited data on their prevalence in Nigeria. In urban settings, where these diseases are endemic and share common biological, ecological, and economic factors, they may impact treatment outcomes and lead to epidemiological synergy. Hence, it is imperative to conduct sero-epidemiological and clinical studies to better understand the disease burden and hidden endemicity, thereby enabling improved prevention and clinical management. Method. Serum samples collected from outpatients between December 2020 and November 2021 in three regions of Nigeria were tested for the presence of IgG antibody seropositivity against ZIKV and FLAVI using immunoblot serological assay. Results. The overall cohort co-circulation antibody seropositivity of ZIKV, FLAVI and malaria was 24.0% (209/871). A total of 19.2% (167/871) of the study participants had ZIKV-seropositive antibodies and 6.2% (54/871) were FLAVI-seropositive, while 40.0% (348/871) of the subjects had malaria parasite antigens. Regional analysis revealed that participants from the southern region had the highest antibody seropositivity against ZIKV (21.7% (33/152)) and FLAVI (8.6% (13/152)), whereas those from the central region had a higher malaria parasite antigen (68.5% (287/419)). Conclusions. This study represents the largest comparative cross-sectional descriptive sero-epidemiological investigation of ZIKV-FLAVI and malaria cocirculation in Nigeria. The findings of this study revealed increased antibody seropositivity, hidden endemicity, and the burden of ZIKV, FLAVI, and malaria co-circulating in Nigeria.

Keywords: IgG; Zika; co-circulation; flavivirus; malaria parasite; sero-epidemiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Arboviral and malaria study sites in Nigeria.
Figure 2
Figure 2
Blood product antibody seropositivity.
Figure 3
Figure 3
Age-specific antibody seropositivity of ZIKV, FLAVI, and malaria cocirculation.
Figure 4
Figure 4
Monthly antibody seropositivity for ZIKV, FLAVI, and malaria during the sampling period.
See this image and copyright information in PMC

References

    1. Nunez-Avellaneda D., Tangudu C., Barrios-Palacios J., Machain-Williams C., Alarcón-Romero L.D.C., Zubillaga-Guerrero M.I., Nunez-Avellaneda S., McKeen L.A., Canche-Aguilar I., Loaeza-Díaz L., et al. Co-Circulation of All Four Dengue Viruses and Zika Virus in Guerrero, Mexico, 2019. Vector-Borne Zoonotic Dis. 2021;21:458–465. doi: 10.1089/vbz.2020.2742. - DOI - PubMed
    1. Fagbami A.H. Zika Virus Infections in Nigeria: Virological and Seroepidemiological Investigations in Oyo State. J. Hyg. 1979;83:2. doi: 10.1017/S0022172400025997. - DOI - PMC - PubMed
    1. WHO Countries and Territories with Current or Previous Zika Virus Transmission. Updated February 2022. [(accessed on 1 February 2023)]. Available online: https://cdn.who.int/media/docs/default-source/documents/emergencies/zika....
    1. Giron S., Franke F., Decoppet A., Cadiou B., Travaglini T., Thirion L., Durand G., Jeannin C., L’ambert G., Grard G., et al. Vector-borne transmission of Zika virus in Europe, southern France, August 2019. Eurosurveillance. 2019;24:1900655. doi: 10.2807/1560-7917.ES.2019.24.45.1900655. - DOI - PMC - PubMed
    1. Otu A., Udoh U., Ita O., Hicks J.P., Ukpeh I., Walley J. Prevalence of Zika and malaria in patients with fever in secondary healthcare facilities in south-eastern Nigeria. Trop. Dr. 2019;50:22–30. doi: 10.1177/0049475519872580. - DOI - PubMed

LinkOut - more resources